Model predicts growth hormone therapy responses in children with short stature

AI Summary

Researchers have developed a model to predict how children with idiopathic short stature may respond to recombinant growth hormone therapy. The work addresses the wide variation in treatment outcomes and could help clinicians and families set expectations.

Idiopathic short stature (ISS) describes children whose height is substantially below the expected range for their age and sex without any identifiable medical cause. Recombinant growth hormone (GH) therapy is often used to support growth, but responses vary widely. While some children experience meaningful catch-up growth, others show more limited improvement, making it difficult for clinicians and families to anticipate treatment benefits and set realistic expectations.